Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for <i>RAS</i> Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial

Abstract

For patients with initially unresectable <i>RAS</i> mutant colorectal liver metastases, bevacizumab combined with mFOLFOX6 increased the resectability of liver metastases and improved response rates and survival compared with mFOLFOX6 alone.